OKYO Other Current Assets vs Net Invested Capital Analysis

OKYO Stock

USD 2.57 0.13 4.81%

OKYO Pharma financial indicator trend analysis is much more than just breaking down OKYO Pharma prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether OKYO Pharma is a good investment. Please check the relationship between OKYO Pharma Other Current Assets and its Net Invested Capital accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OKYO Pharma Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private.

Other Current Assets vs Net Invested Capital

Other Current Assets vs Net Invested Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of OKYO Pharma Other Current Assets account and Net Invested Capital. At this time, the significance of the direction appears to have almost no relationship.

The correlation between OKYO Pharma's Other Current Assets and Net Invested Capital is 0.17. Overlapping area represents the amount of variation of Other Current Assets that can explain the historical movement of Net Invested Capital in the same time period over historical financial statements of OKYO Pharma Ltd, assuming nothing else is changed. The correlation between historical values of OKYO Pharma's Other Current Assets and Net Invested Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Assets of OKYO Pharma Ltd are associated (or correlated) with its Net Invested Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Invested Capital has no effect on the direction of Other Current Assets i.e., OKYO Pharma's Other Current Assets and Net Invested Capital go up and down completely randomly.

Correlation Coefficient

0.17

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Other Current Assets

Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.

Net Invested Capital

The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.

Most indicators from OKYO Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into OKYO Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OKYO Pharma Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private.

At this time, OKYO Pharma's Selling General Administrative is very stable compared to the past year. As of the 4th of November 2025, Issuance Of Capital Stock is likely to grow to about 3 M, though Tax Provision is likely to grow to (3.1 M).

	2022	2023	2024	2025 (projected)
Reconciled Depreciation	3.8K	3.9K	2.6K	3.1K
Research Development	6.3M	8.2M	2.3M	3.5M

Reconciled Depreciation Research Development

OKYO Pharma fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Investments	Intangible Assets	Other Current Liab	Good Will	Net Receivables	Inventory	Common Stock	Net Tangible Assets	Net Invested Capital	Capital Stock
Total Assets		-0.51	0.99	0.85	-0.81	0.71	-0.45	0.8	0.97	0.81	-0.33	-0.06	0.22	-0.46	-0.51	0.8	0.14	0.6	-0.42	0.74	-0.48	-0.06	-0.26	0.09	0.26	-0.6
Total Current Liabilities	-0.51		-0.64	-0.52	0.45	-0.81	0.91	-0.42	-0.52	-0.47	0.62	-0.44	-0.08	0.72	1.0	-0.38	-0.16	-0.18	0.64	-0.32	0.89	0.8	0.77	0.25	-0.77	0.88
Total Stockholder Equity	0.99	-0.64		0.86	-0.8	0.78	-0.56	0.79	0.96	0.81	-0.41	0.02	0.22	-0.54	-0.64	0.78	0.16	0.57	-0.49	0.72	-0.58	-0.19	-0.37	0.03	0.37	-0.69
Property Plant And Equipment Net	0.85	-0.52	0.86		-0.49	0.59	-0.43	0.48	0.92	0.6	-0.32	-0.16	0.05	-0.56	-0.52	0.58	0.12	0.26	-0.47	0.38	-0.44	-0.15	-0.26	0.02	0.22	-0.59
Net Debt	-0.81	0.45	-0.8	-0.49		-0.78	0.4	-1.0	-0.63	-0.87	-0.01	-0.01	-0.21	0.3	0.45	-0.86	-0.51	-0.4	0.32	-0.94	0.47	0.02	0.23	-0.2	-0.31	0.47
Retained Earnings	0.71	-0.81	0.78	0.59	-0.78		-0.7	0.76	0.63	0.79	-0.24	0.19	-0.05	-0.59	-0.81	0.72	0.51	0.2	-0.6	0.7	-0.75	-0.42	-0.73	-0.19	0.49	-0.87
Accounts Payable	-0.45	0.91	-0.56	-0.43	0.4	-0.7		-0.42	-0.44	-0.45	0.63	-0.39	-0.01	0.67	0.91	-0.37	-0.13	-0.16	0.27	-0.25	0.86	0.7	0.64	0.15	-0.9	0.74
Cash	0.8	-0.42	0.79	0.48	-1.0	0.76	-0.42		0.62	0.87	0.02	-0.01	0.19	-0.28	-0.42	0.86	0.51	0.4	-0.24	0.94	-0.46	0.02	-0.21	0.21	0.32	-0.45
Non Current Assets Total	0.97	-0.52	0.96	0.92	-0.63	0.63	-0.44	0.62		0.69	-0.46	-0.07	0.19	-0.5	-0.52	0.67	-0.03	0.6	-0.46	0.56	-0.47	-0.11	-0.29	0.02	0.23	-0.62
Cash And Short Term Investments	0.81	-0.47	0.81	0.6	-0.87	0.79	-0.45	0.87	0.69		-0.07	0.01	0.05	-0.53	-0.47	0.99	0.44	0.32	-0.3	0.78	-0.48	-0.11	-0.3	0.2	0.33	-0.51
Common Stock Shares Outstanding	-0.33	0.62	-0.41	-0.32	-0.01	-0.24	0.63	0.02	-0.46	-0.07		-0.34	-0.11	0.44	0.62	0.0	0.62	-0.6	0.27	0.1	0.59	0.59	0.47	0.17	-0.55	0.53
Non Current Liabilities Total	-0.06	-0.44	0.02	-0.16	-0.01	0.19	-0.39	-0.01	-0.07	0.01	-0.34		0.62	-0.32	-0.44	-0.02	-0.09	0.1	-0.25	-0.02	-0.22	-0.56	-0.22	-0.1	0.5	-0.18
Other Current Assets	0.22	-0.08	0.22	0.05	-0.21	-0.05	-0.01	0.19	0.19	0.05	-0.11	0.62		-0.15	-0.08	0.12	-0.17	0.36	-0.13	0.2	0.16	-0.06	0.31	0.19	0.17	0.17
Other Stockholder Equity	-0.46	0.72	-0.54	-0.56	0.3	-0.59	0.67	-0.28	-0.5	-0.53	0.44	-0.32	-0.15		0.72	-0.48	-0.1	-0.04	0.44	-0.11	0.6	0.58	0.5	-0.1	-0.64	0.55
Total Liab	-0.51	1.0	-0.64	-0.52	0.45	-0.81	0.91	-0.42	-0.52	-0.47	0.62	-0.44	-0.08	0.72		-0.38	-0.16	-0.18	0.64	-0.32	0.89	0.8	0.77	0.25	-0.77	0.88
Total Current Assets	0.8	-0.38	0.78	0.58	-0.86	0.72	-0.37	0.86	0.67	0.99	0.0	-0.02	0.12	-0.48	-0.38		0.43	0.32	-0.24	0.78	-0.37	-0.02	-0.2	0.22	0.27	-0.41
Short Term Investments	0.14	-0.16	0.16	0.12	-0.51	0.51	-0.13	0.51	-0.03	0.44	0.62	-0.09	-0.17	-0.1	-0.16	0.43		-0.48	-0.18	0.53	-0.17	0.06	-0.2	-0.04	0.07	-0.22
Intangible Assets	0.6	-0.18	0.57	0.26	-0.4	0.2	-0.16	0.4	0.6	0.32	-0.6	0.1	0.36	-0.04	-0.18	0.32	-0.48		-0.16	0.47	-0.19	0.01	-0.11	-0.01	0.09	-0.26
Other Current Liab	-0.42	0.64	-0.49	-0.47	0.32	-0.6	0.27	-0.24	-0.46	-0.3	0.27	-0.25	-0.13	0.44	0.64	-0.24	-0.18	-0.16		-0.33	0.45	0.53	0.65	0.4	-0.12	0.72
Good Will	0.74	-0.32	0.72	0.38	-0.94	0.7	-0.25	0.94	0.56	0.78	0.1	-0.02	0.2	-0.11	-0.32	0.78	0.53	0.47	-0.33		-0.32	0.1	-0.24	0.0	0.12	-0.44
Net Receivables	-0.48	0.89	-0.58	-0.44	0.47	-0.75	0.86	-0.46	-0.47	-0.48	0.59	-0.22	0.16	0.6	0.89	-0.37	-0.17	-0.19	0.45	-0.32		0.62	0.67	0.13	-0.66	0.78
Inventory	-0.06	0.8	-0.19	-0.15	0.02	-0.42	0.7	0.02	-0.11	-0.11	0.59	-0.56	-0.06	0.58	0.8	-0.02	0.06	0.01	0.53	0.1	0.62		0.67	0.24	-0.74	0.61
Common Stock	-0.26	0.77	-0.37	-0.26	0.23	-0.73	0.64	-0.21	-0.29	-0.3	0.47	-0.22	0.31	0.5	0.77	-0.2	-0.2	-0.11	0.65	-0.24	0.67	0.67		0.53	-0.46	0.89
Net Tangible Assets	0.09	0.25	0.03	0.02	-0.2	-0.19	0.15	0.21	0.02	0.2	0.17	-0.1	0.19	-0.1	0.25	0.22	-0.04	-0.01	0.4	0.0	0.13	0.24	0.53		0.09	0.48
Net Invested Capital	0.26	-0.77	0.37	0.22	-0.31	0.49	-0.9	0.32	0.23	0.33	-0.55	0.5	0.17	-0.64	-0.77	0.27	0.07	0.09	-0.12	0.12	-0.66	-0.74	-0.46	0.09		-0.5
Capital Stock	-0.6	0.88	-0.69	-0.59	0.47	-0.87	0.74	-0.45	-0.62	-0.51	0.53	-0.18	0.17	0.55	0.88	-0.41	-0.22	-0.26	0.72	-0.44	0.78	0.61	0.89	0.48	-0.5

Click cells to compare fundamentals

OKYO Pharma Account Relationship Matchups

OKYO Pharma fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	7.1M	4.3M	5.2M	1.5M	3.7M	3.5M
Total Current Liabilities	1.7M	1.4M	7.3M	7.4M	9.2M	9.7M
Total Stockholder Equity	5.3M	2.9M	(2.1M)	(5.9M)	(5.5M)	(5.3M)
Property Plant And Equipment Net	104.6K	5.2K	7.2K	3.4K	2.0K	1.9K
Net Debt	(6.8M)	(2.7M)	(1.8M)	(826.8K)	(1.6M)	(1.6M)
Retained Earnings	(106.0M)	(112.4M)	(125.7M)	(142.5M)	(143.0M)	(135.9M)
Accounts Payable	211.0K	517.7K	1.0M	6.1M	7.9M	8.3M
Cash	6.9M	2.7M	4.0M	826.8K	1.6M	1.5M
Non Current Assets Total	104.6K	5.2K	7.2K	3.4K	2.0K	1.9K
Cash And Short Term Investments	6.9M	2.7M	4.0M	826.8K	1.6M	1.5M
Common Stock Shares Outstanding	10.4M	15.1M	22.3M	29.3M	39.5M	41.5M
Liabilities And Stockholders Equity	7.1M	4.3M	5.2M	1.5M	3.7M	3.5M
Other Current Assets	92.8K	712.7K	934.0	130.1K	225.4K	165.6K
Other Stockholder Equity	24.5M	2.4M	131.4M	148.0M	146.7M	154.1M
Total Liab	1.8M	1.4M	7.3M	7.4M	9.2M	9.7M
Total Current Assets	7.0M	4.3M	5.2M	1.5M	3.7M	3.5M
Other Current Liab	1.4M	835.5K	4.0M	1.3M	1.3M	723.2K
Net Receivables	4.5K	883.4K	980.1K	580.9K	1.9M	2.0M
Inventory	(792.0)	34.0	(1.5K)	170.3K	153.3K	160.9K
Accumulated Other Comprehensive Income	12.8M	(11.0M)	(7.7M)	(11.3M)	(11.5M)	(10.9M)
Common Stock	111.6M	124.0M	131.4M	143.1M	146.7M	114.7M
Net Tangible Assets	255.4K	(113.0K)	3.9M	2.2M	2.6M	1.8M
Net Invested Capital	3.9M	2.9M	161.9K	(5.9M)	(5.5M)	(5.3M)
Capital Stock	111.6M	124.0M	131.4M	143.1M	146.7M	124.6M
Net Working Capital	3.8M	2.9M	(2.1M)	(5.9M)	(5.6M)	(5.3M)
Property Plant And Equipment Gross	77.5K	7.4K	15.3K	10.5K	10.5K	20.1K

When determining whether OKYO Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of OKYO Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Okyo Pharma Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Okyo Pharma Ltd Stock:

How To Invest In OKYO

Details

Is OKYO Stock a good investment?

Details

What is OKYO Pharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OKYO Pharma Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private.

You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OKYO Pharma. If investors know OKYO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OKYO Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.12)

Return On Assets

(1.70)

Return On Equity

(29.69)

The market value of OKYO Pharma is measured differently than its book value, which is the value of OKYO that is recorded on the company's balance sheet. Investors also form their own opinion of OKYO Pharma's value that differs from its market value or its book value, called intrinsic value, which is OKYO Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OKYO Pharma's market value can be influenced by many factors that don't directly affect OKYO Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between OKYO Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if OKYO Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OKYO Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

OKYO Other Current Assets vs Net Invested Capital Analysis

Other Current Assets vs Net Invested Capital

Other Current Assets vs Net Invested Capital Correlation Analysis

Correlation Coefficient

Other Current Assets

Net Invested Capital

OKYO Pharma fundamental ratios Correlations

OKYO Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

OKYO Pharma fundamental ratios Accounts

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Total Current Liabilities
Total Stockholder Equity	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Cash And Short Term Investments
Non Current Assets Total	+ 0.97	Total Assets
Non Current Assets Total	+ 0.96	Total Stockholder Equity
Good Will	+ 0.94	Cash

Cash	- 1.0	Net Debt
Good Will	- 0.94	Net Debt
Net Invested Capital	- 0.9	Accounts Payable
Capital Stock	- 0.87	Retained Earnings
Cash And Short Term Investments	- 0.87	Net Debt
Total Current Assets	- 0.86	Net Debt